Gondo George C, Noe Megan H, Bell Stacie J, Ritchlin Christopher T
National Psoriasis Foundation, Portland, OR, USA.
Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
J Psoriasis Psoriatic Arthritis. 2022 Jan;7(1):17-23. doi: 10.1177/24755303211067822. Epub 2021 Dec 10.
Development and dissemination of novel COVID-19 vaccines represent an opportunity to end the COVID-19 pandemic by vaccinating an estimated 80% of the population. This study examines perceptions, and demographic and clinical factors influencing the likelihood of adults with psoriasis receiving a novel COVID-19 vaccine. A cross sectional study conducted from October-November 2020 of 1405 adults with psoriatic disease with prior contact to a patient advocacy organization. The main outcome of interest was the likelihood of receiving a COVID-19 vaccine. Chi-square tests and logistic regression examined the relationship between individual characteristics and likelihood of receiving a COVID-19 vaccine. Most participants (65%) received a flu vaccination in the last 12 months and were (64.2%) likely to receive a COVID-19 vaccine, while 35.9% reported being unlikely receive a vaccine. Likelihood of COVID-19 vaccination was associated with receiving the flu vaccine, race, ethnicity, sex, BMI, age, income, severity of PsO and PsA. When controlling for ethnicity, race, male sex, overweight/obese status, age, biologic use, disease type, comorbidities linked with worse COVID-19 outcomes, PsA symptoms, and skin disease severity, individuals who received the flu vaccine and those with annual household income over $75,000 were most likely to receive a COVID-19 vaccine. Vaccine hesitancy among individuals with psoriatic disease is considerable. Dermatologists and rheumatologists can increase COVID-19 vaccine uptake by actively engaging their patients on this topic using guidance published by the National Psoriasis Foundation on the management of psoriatic disease during the COVID-19 pandemic.
新型新冠疫苗的研发和推广为通过为约80%的人口接种疫苗来终结新冠疫情提供了契机。本研究调查了银屑病成年患者对新型新冠疫苗的看法以及影响他们接种疫苗可能性的人口统计学和临床因素。这是一项横断面研究，于2020年10月至11月对1405名曾与患者权益倡导组织有过接触的银屑病患者进行。主要关注的结果是接种新冠疫苗的可能性。卡方检验和逻辑回归分析了个体特征与接种新冠疫苗可能性之间的关系。大多数参与者（65%）在过去12个月内接种过流感疫苗，并且有64.2%的可能性接种新冠疫苗，而35.9%的人表示不太可能接种疫苗。接种新冠疫苗的可能性与接种流感疫苗、种族、民族、性别、体重指数、年龄、收入、银屑病和银屑病关节炎的严重程度有关。在控制种族、民族、男性性别、超重/肥胖状态、年龄、生物制剂使用、疾病类型、与新冠不良预后相关的合并症、银屑病关节炎症状和皮肤病严重程度后，接种流感疫苗的人和家庭年收入超过75000美元的人最有可能接种新冠疫苗。银屑病患者中存在相当程度的疫苗犹豫现象。皮肤科医生和风湿病医生可以利用国家银屑病基金会发布的关于新冠疫情期间银屑病管理的指南，积极与患者就这一话题进行沟通，从而提高新冠疫苗的接种率。
